Skip to search formSkip to main contentSkip to account menu

HKI 272

Known as: HKI-272, HKI272 
An orally available, 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile, irreversible inhibitor of the HER-2 receptor tyrosine kinase with potential… 
National Institutes of Health

Related topics

Related topics

1 relation
neratinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.
Neratinib (HKI-272) is a small molecule tyrosine kinase inhibitor of the ErbB receptor family currently in Phase III clinical… 
2012
2012
Preformulation stability study of the EGFR inhibitor HKI-272 (Neratinib) and mechanism of degradation
The stability in solution of HKI-272 (Neratinib) was studied as a function of pH. The drug is most stable from pH 3 to 4, and… 
2012
2012
A New and Improved Process for N-(4-Chloro-3-cyano-7-ethoxyquinolin-6-yl)acetamide
A new and improved synthetic route to N-(4-chloro-3-cyano-7-ethoxyquinolin-6-yl)acetamide (1) is described on a kilogram scale… 
2011
2011
S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.
Background: Neratinib (N), an irreversible pan-tyrosine kinase inhibitor (TKI), with activity against HER1, -2 and -4, has shown… 
2010
2010
Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy
Background: Neratinib (HKI-272) is an irreversible pan-ErbB tyrosine kinase inhibitor that blocks downstream signaling of the… 
Review
2010
Review
2010
Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.
Constitutive activation of the EGFR/RAS/PI3K cell-signaling pathway that may occur through molecular aberrations in core pathway… 
2009
2009
Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+ Metastatic Breast Cancer.
Background: Neratinib (HKI-272), an irreversible pan-ErbB inhibitor of the tyrosine kinase receptors ErbB1, -2 and -4, has shown… 
2009
2009
Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer.
Background: The irreversible pan-ErbB tyrosine kinase inhibitor neratinib (HKI-272) potently blocks downstream signaling of the… 
2009
2009
Tolerability and safety of oral neratinib (HKI-272) in Japanese patients with advanced solid tumors.
e14505 Background: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor. In non-Japanese pts… 
2009
2009
Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors.
e14554 Background: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor. Preclinical studies have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)